anastrozole has been researched along with Female Genital Diseases in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The lower incidence of gynecologic adverse events and interventions with anastrozole and the early occurrence of these events provide further support for using anastrozole as the initial adjuvant treatment for early hormone receptor-positive breast cancer." | 3.75 | A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. ( Baum, M; Cuzick, J; Distler, W; Duffy, SR; Howell, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duffy, SR | 1 |
| Distler, W | 1 |
| Howell, A | 1 |
| Cuzick, J | 1 |
| Baum, M | 1 |
1 other study available for anastrozole and Female Genital Diseases
| Article | Year |
|---|---|
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genital Diseases, Female; Hu | 2009 |